Radiosynthesis, Biological Evaluation, and Preclinical Study of a 68Ga-Labeled Cyclic RGD Peptide as an Early Diagnostic Agent for Overexpressed αvβ3 Integrin Receptors in Non-Small-Cell Lung Cancer

<div>Biodistribution of [68Ga]Ga-DOTA-E(cRGDfK)2 in percentage of ID/g of organs at 30, 60, and 90 min postinjection in αvβ3-positive tumor-bearing mice. Values are mean ± standard deviation (n = 3 per group) (a). Tumor-to-organ ratio at 30, 60, and 90 min postinjection (b).</div>

Contrast Media & Molecular Imaging

fig10

Figure 10

Figure 10: Radiosynthesis, Biological Evaluation, and Preclinical Study of a 68Ga-Labeled Cyclic RGD Peptide as an Early Diagnostic Agent for Overexpressed αvβ3 Integrin Receptors in Non-Small-Cell Lung Cancer

Figure 10 | Radiosynthesis, Biological Evaluation, and Preclinical Study of a 68Ga-Labeled Cyclic RGD Peptide as an Early Diagnostic Agent for Overexpressed αvβ3 Integrin Receptors in Non-Small-Cell Lung Cancer 